Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
71.70
+0.97 (1.37%)
At close: Jul 25, 2025, 4:00 PM
71.75
+0.05 (0.07%)
After-hours: Jul 25, 2025, 7:57 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
7.19
Revenue / Employee
3,919,133 DKK
Employees
77,349
Market Cap
315.59B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 43.21B |
NVO News
- 8 hours ago - 3 'Wide Moat' SWANs - Seeking Alpha
- 13 hours ago - European regulatory authority adopts positive opinion for Novo Nordisk's Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors - GlobeNewsWire
- 1 day ago - Novo Nordisk: Undervalued Despite Strong Growth Trend & Solid Market Share - Seeking Alpha
- 1 day ago - This Weight-Loss Stock Sank After Earnings. It's Still a Risk for Eli Lilly, Novo Nordisk. - Barrons
- 2 days ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 2 days ago - Novo Nordisk: The Market Hasn't Given It Enough Respect - Seeking Alpha
- 3 days ago - Novo Nordisk's Moat Is Deeper Than You Think - Seeking Alpha
- 5 days ago - Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management - GlobeNewsWire